Immucell (ICCC) Other Non-Current Assets (2010 - 2026)
Immucell's (ICCC) quarterly Other Non-Current Assets came in at $37686.0 in Q4 2025, up 12.94% YoY from $33368.0 in Q4 2024, and down 15.02% on a QoQ basis from $44345.0 in Q3 2025.
Immucell (ICCC) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Other Non-Current Assets data on file, last reported at $37686.0 in Q4 2025.
- Quarterly Other Non-Current Assets rose 12.94% year-over-year to $37686.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37686.0 (up 12.94% YoY) and the FY2025 annual result came in at $37686.0, up 12.94% from the prior year.
- Other Non-Current Assets slipped to $37686.0 in Q4 2025, from $44345.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $14.0 million in Q4 2022 to a low of $800.0 in Q1 2021.
- A 5-year average of $738510.2 and a median of $37682.5 in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 53488.96% — and 2023, when it plunged 99.59%.
- Tracing ICCC's Other Non-Current Assets over 5 years: stood at $26115.0 in 2021, then soared by 53488.96% to $14.0 million in 2022, then sank by 99.59% to $57655.0 in 2023, then slumped by 42.12% to $33368.0 in 2024, then climbed by 12.94% to $37686.0 in 2025.
- The last three Other Non-Current Assets figures came in at $37686.0 (Q4 2025), $44345.0 (Q3 2025), and $53619.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | 31,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31,658.00 |
| Dec 31, 2025 | 37,686.00 |
| Sep 30, 2025 | 44,345.00 |
| Jun 30, 2025 | 53,619.00 |
| Mar 31, 2025 | 45,417.00 |
| Dec 31, 2024 | 33,368.00 |
| Sep 30, 2024 | 28,899.00 |
| Jun 30, 2024 | 37,679.00 |
| Mar 31, 2024 | 46,248.00 |
| Dec 31, 2023 | 57,655.00 |
| Sep 30, 2023 | 70,041.00 |
| Jun 30, 2023 | 82,459.00 |
| Mar 31, 2023 | 87,781.00 |
| Dec 31, 2022 | 13.99 Mn |
| Sep 30, 2022 | 24,567.00 |
| Jun 30, 2022 | 23,783.00 |
| Mar 31, 2022 | 22,999.00 |
| Dec 31, 2021 | 26,115.00 |
| Sep 30, 2021 | 26,596.00 |
| Jun 30, 2021 | 25,391.00 |